211914-51-1
211914-51-1 structure
- Name: Dabigatran (BIBR 953)
- Chemical Name: dabigatran
- CAS Number: 211914-51-1
- Molecular Formula: C25H25N7O3
- Molecular Weight: 471.511
- Catalog: API Blood system medication Anticoagulant and antiplatelet drugs
- Create Date: 2018-02-08 08:00:00
- Modify Date: 2026-07-02 17:04:16
-
Dabigatran(BIB-953; BIBR 953ZW) is a reversible and selective, direct thrombin inhibitor (DTI) with Ki value of 4.5 nM.IC50 Value: 4.5 nM (Ki); 10 nM(Thrombin-induced platelet aggregation) [1]Target: thrombinin vitro: Dabigatran selectively and reversibly inhibited human thrombin(Ki: 4.5 nM) as well as thrombin-induced platelet aggregation (IC(50): 10 nM), while showing no inhibitory effect on other platelet-stimulating agents.Thrombin generation in platelet-poor plasma (PPP), measured as the endogenous thrombin potential (ETP) was inhibited concentration-dependently (IC(50): 0.56 microM). Dabigatran demonstrated concentration-dependent anticoagulant effects in various species in vitro, doubling the activated partial thromboplastin time (aPTT), prothrombin time (PT) and ecarin clotting time (ECT) in human PPP at concentrations of 0.23, 0.83 and 0.18 microM, respectively [1]. in vivo: Dabigatran prolonged the aPTT dose-dependently after intravenous administration in rats (0.3, 1 and 3 mg/kg) and rhesus monkeys (0.15, 0.3 and 0.6 mg/kg). Dose- and time-dependent anticoagulant effects were observed with dabigatran etexilate administered orally to conscious rats (10, 20 and 50 mg/kg) or rhesus monkeys (1, 2.5 or 5 mg/kg), with maximum effects observed between 30 and 120 min after administration, respectively [1]. Patients treated with dabigatran etexilate experienced fewer ischaemic strokes (3.74 dabigatran etexilate vs 3.97 warfarin) and fewer combined intracranial haemorrhages and haemorrhagic strokes (0.43 dabigatran etexilate vs 0.99 warfarin) per 100 patient-years [2].Clinical trial: An Evaluation of the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate in Hemodialysis Patients . Phase1
| Name | dabigatran |
|---|---|
| Synonyms |
BIB-953
3-[[2-[(4-carbamimidoylanilino)methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoic acid Dabigatran in acetonitrile 3-[[2-[(4-cbamimidoylanilino)methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoic acid Dabigatran UNII-I0VM4M70GC Dabigatran //BP b-Alanine,N-[[2-[[[4-(aminoiminomethyl)phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl Dabigtan -IP/BP/HIS Dabigatran API Dabigatran BIBR-953 N-[[2-[[[4-(Aminoiminomethyl)phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-beta-alanine 3-[2-[[(4-Cbamimidoylphenyl)amino]methyl]-1-methyl-N-(2-pyridyl)benzimidazole-5-cboxamido]propanoic Acid Dabiga oup BIBR953;BIBR 953;BIBR-953 Dabigatran etexilate impurity189 BIBR 953(Dabigatran) Dabigatran etexilate-1 Dabigatran3-(2-((4-cbamimidoylphenylamino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-cboxamido)propanoic acid N- (2-{ (4-cbaMiMidoylphenyl)amino Methyl}-1-Met N-[[2-[[[4-(AMinoiMinoMethyl)phenyl]amino]Methyl]-1-Methyl-1H-benzo[d]iMidazol-5-yl]carbonyl]-N-pyridin-2-yl-beta-alanine 3-[[2-[(4-cbamimidoylanilino)methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoic acid 3-(2-((4-cbamimidoylphenylamino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-cboxamido)propanoic acid BIBR 953ZW 3-[[2-[[(4-cbaMiMidoylphenyl)amino]Methyl]-1-Met Dabigatran(BIB-953 3-[[2-[[(4-cbamimidoylphenyl)amino]methyl]-1-methyl-benzoimidazole-5-carbonyl]-pyridin-2-yl-amino]propanoic acid Dabigatran Etexilate Mesilate ethyl 3-(2-(((4-(N'-((hexan-2-yloxy)carbonyl)cbamimidoyl)phenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-cboxamido)propanoate Dabigatran Standd Dabigatran Impurity b Dabigatran etexilate impurity1513 Dabigatran Impurity U Dabigatran (Acid) N-[(2-{[(4-cbaMiMidoylphenyl)amino]Methyl}-1-Methyl-1HbenziMidazol- 5-yl)carbonyl]-N-pyridin-2-yl-beta-alanine BIBR 953 (Dabigatran, Pradaxa) 3-[[2-[(4-cbamimidoylanilino)methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoic BIBR 953;BIBR 953ZW;BIBR953;BIB-953 3-[[2-[[(4-cbaMiMidoylphenyl)amino]Methyl]-1-Methyl-benzoiMidazole-5-carbonyl]-pyridin-2-yl-amino] Dabigatran base Desethyl Dabigatran Etexilate Impurity D Dabigatran Ester Impurity B β-Alanine,N-[[2-[[[4-(aMinoiMinoMethyl)phenyl]amino]Methyl]-1-Methyl-1H-benziMidazol-5-yl]carbonyl]-N-2-pyridinyl DabigatranQ: What is Dabigatran Q: What is the CAS Number of Dabigatran Q: What is the storage condition of Dabigatran Q: What e the applications of Dabigatran Dabigatran AKSci B955 D4-Dabigatran hydrochloride N-[(2-{[(4-cbamimidoylphenyl)amino]methyl}-1-methyl-1H-ben |
| Description | Dabigatran(BIB-953; BIBR 953ZW) is a reversible and selective, direct thrombin inhibitor (DTI) with Ki value of 4.5 nM.IC50 Value: 4.5 nM (Ki); 10 nM(Thrombin-induced platelet aggregation) [1]Target: thrombinin vitro: Dabigatran selectively and reversibly inhibited human thrombin(Ki: 4.5 nM) as well as thrombin-induced platelet aggregation (IC(50): 10 nM), while showing no inhibitory effect on other platelet-stimulating agents.Thrombin generation in platelet-poor plasma (PPP), measured as the endogenous thrombin potential (ETP) was inhibited concentration-dependently (IC(50): 0.56 microM). Dabigatran demonstrated concentration-dependent anticoagulant effects in various species in vitro, doubling the activated partial thromboplastin time (aPTT), prothrombin time (PT) and ecarin clotting time (ECT) in human PPP at concentrations of 0.23, 0.83 and 0.18 microM, respectively [1]. in vivo: Dabigatran prolonged the aPTT dose-dependently after intravenous administration in rats (0.3, 1 and 3 mg/kg) and rhesus monkeys (0.15, 0.3 and 0.6 mg/kg). Dose- and time-dependent anticoagulant effects were observed with dabigatran etexilate administered orally to conscious rats (10, 20 and 50 mg/kg) or rhesus monkeys (1, 2.5 or 5 mg/kg), with maximum effects observed between 30 and 120 min after administration, respectively [1]. Patients treated with dabigatran etexilate experienced fewer ischaemic strokes (3.74 dabigatran etexilate vs 3.97 warfarin) and fewer combined intracranial haemorrhages and haemorrhagic strokes (0.43 dabigatran etexilate vs 0.99 warfarin) per 100 patient-years [2].Clinical trial: An Evaluation of the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate in Hemodialysis Patients . Phase1 |
|---|---|
| Related Catalog | |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 797.1±70.0 °C at 760 mmHg |
| Melting Point | 268-272ºC |
| Molecular Formula | C25H25N7O3 |
| Molecular Weight | 471.511 |
| Flash Point | 435.9±35.7 °C |
| Exact Mass | 471.201874 |
| PSA | 150.22000 |
| LogP | 0.79 |
| Vapour Pressure | 0.0±2.9 mmHg at 25°C |
| Index of Refraction | 1.694 |
| Storage condition | Refrigerator, Under Inert Atmosphere |